There is great interest in tumor stem cells (TSCs) as potential therapeutic targets; however, cancer therapies targeting TSCs are limited. A drawback is that TSC markers are often shared by normal stem cells (NSCs) 1-4 ; thus, therapies that target these markers may cause severe injury to normal tissues. To identify a potential TSC-specific marker, we focused on doublecortinlike kinase 1 (Dclk1). Dclk1 was reported as a candidate NSC marker in the gut 5 Recent studies have identified intestinal stem cell markers 3,9,10 , such as Lgr5, Bmi1 and CD133. Accumulating evidence also supports the existence of TSCs 1,2,11-16 , which resemble NSCs in their capacity for self-renewal and continuously replenish tumor progeny 17, 18 . Previously reported TSC markers are shared by NSCs in the intestine 1-4 ; thus, identifying TSC-specific markers is an important challenge.
l e t t e r s
There is great interest in tumor stem cells (TSCs) as potential therapeutic targets; however, cancer therapies targeting TSCs are limited. A drawback is that TSC markers are often shared by normal stem cells (NSCs) [1] [2] [3] [4] ; thus, therapies that target these markers may cause severe injury to normal tissues. To identify a potential TSC-specific marker, we focused on doublecortinlike kinase 1 (Dclk1). Dclk1 was reported as a candidate NSC marker in the gut 5, 6 , but recent reports have implicated it as a marker of differentiated cells (for example, Tuft cells) 7, 8 . Using lineage-tracing experiments, we show here that Dclk1 does not mark NSCs in the intestine but instead marks TSCs that continuously produce tumor progeny in the polyps of Apc Min/+ mice. Specific ablation of Dclk1-positive TSCs resulted in a marked regression of polyps without apparent damage to the normal intestine. Our data suggest the potential for developing a therapy for colorectal cancer based on targeting Dclk1-positive TSCs.
Recent studies have identified intestinal stem cell markers 3, 9, 10 , such as Lgr5, Bmi1 and CD133. Accumulating evidence also supports the existence of TSCs 1, 2, [11] [12] [13] [14] [15] [16] , which resemble NSCs in their capacity for self-renewal and continuously replenish tumor progeny 17, 18 . Previously reported TSC markers are shared by NSCs in the intestine [1] [2] [3] [4] ; thus, identifying TSC-specific markers is an important challenge.
Dclk1 was reported as a putative intestinal NSC marker located at the '+4 position' , just above Paneth cells 5, 6, 19 . However, recent reports have suggested that Dclk1 marks Tuft cells 7, 8 , and it remains unclear whether Dclk1 marks NSCs. Furthermore, the presence of Dclk1-positive cells in mouse intestinal tumors and human colorectal carcinomas (CRCs) has been reported 6, 20 ; however, the potential capacity of these cells for tumorigenesis is also unknown.
In this study, we found that Dclk1-positive cells were scattered throughout the intestinal epithelium, but they were most frequently observed in the lower crypt in normal mouse and human intestines, as previously reported 6, 19 ( Supplementary Fig. 1a,b,d ). Dclk1-positive cells were also scattered throughout the intestinal polyps of Apc Min/+ mice and human CRCs ( Supplementary Fig. 1c ,e-h).
To investigate the stemness of Dclk1-positive cells in normal intestines and during intestinal tumorigenesis, we generated knockin mice by integrating a CreERT2-IRES-EGFP cassette at the first ATG codon of Dclk1 (creating Dclk1 CreERT2/+ mice; Supplementary Fig. 2 ). Dclk1 CreERT2/CreERT2 mice were healthy ( Supplementary Fig. 3 ), in accordance with a previous report 21 . As reported 6, 20 , Dclk1-positive cells were distinct from other epithelial cell populations ( Supplementary Fig. 4) .
To test whether Dclk1 marks NSCs in the normal intestine, we performed tamoxifen-induced Cre-mediated lineage tracing 22, 23 in the small intestine (Fig. 1a) and colon ( Supplementary Fig. 5 ) of Dclk1 CreERT2/+ ; Rosa26R mice. No LacZ-labeled cells were detected in the absence of tamoxifen injection (data not shown). One day after injection, scattered LacZ-labeled blue cells were found most frequently in the lower crypt, in accordance with our immunohistochemical data ( Fig. 1b-d) . However, the majority of blue cells shifted toward the villus tip on a daily basis, accompanied by a decrease in their numbers (Fig. 1b-e) . These data suggest that most Dclk1-positive cells originate in the lower crypt, migrate upward and are shed around the villus tip within a few weeks. We could not detect bromodeoxyuridine (BrdU) incorporation in Dclk1-positive cells in the normal intestine (Fig. 1f) . Collectively, these data suggest that Dclk1 is not a stem cell marker in the normal intestine.
Subsequently, we tested the potential stemness of Dclk1-positive cells during regeneration after mucosal injury caused by irradiation or dextran sulfate sodium exposure ( Supplementary  Fig. 6 ). We found that an extremely small number of blue stripes comprised LacZ-labeled Dclk1-positive cell lineages in each experiment. Thus, Dclk1-positive cells rarely produced progeny during mucosal regeneration, and their potential stemness was strictly limited.
We then investigated whether Dclk1 marks intestinal TSCs. Unexpectedly, lineage-tracing analyses of Dclk1 CreERT2/+ ; Rosa26R; Apc Min/+ mice showed that polyps were occupied by LacZ-labeled blue cells (blue polyps) with scattered LacZ expression in the normal intestine 7 d after tamoxifen injection (Fig. 2a-d and Supplementary  Fig. 7 ). This finding highlighted a unique character of Dclk1-expressing cells, which was not found in studies of Lgr5-EGFP-IRES-CreERT2 knockin mice expressing a representative intestinal NSC and TSC marker 4, 9, 24 . In Lgr5 CreERT2/+ ; Rosa26R; Apc Min/+ mice, numerous blue stripes and polyps developed, comprising LacZ-labeled Lgr5-positive cell lineages (Fig. 2e-g ). We traced LacZ expression in the polyps of Dclk1 CreERT2/+ ; Rosa26R; Apc Min/+ mice over time. One day after npg l e t t e r s tamoxifen injection, 3.1% of tumor cells were labeled with LacZ ( Fig. 2h) . Labeled cells at the polyp base then expanded daily to the luminal side and eventually occupied the whole polyp in 5-7 d (Fig. 2i-l) . This rapid renewal of the tumor epithelium was also observed in the polyps from Lgr5 CreERT2/+ ; Rosa26R; Apc Min/+ mice and BrdU-pulsed Apc Min/+ mice ( Supplementary Fig. 8) . Notably, the number of blue polyps did not decrease by day 105 (Fig. 2m,n) . Apc Min/+ ; Dclk1 CreERT2/CreERT2 mice showed the same number and size of polyps as Apc Min/+ mice, suggesting that insertion of the CreERT2 cassette did not affect the potential role of Dclk1 during tumorigenesis ( Supplementary Fig. 9 ). Collectively, these data clearly indicate that Dclk1 marks TSCs that are capable of self-renewal and producing tumor progeny over a prolonged period. Next, we examined the character of Dclk1-positive cells in the tumors. In contrast to their counterparts in the normal intestine, a small proportion of Dclk1-positive tumor cells expressed proliferation markers, particularly at the polyp base ( Fig. 3a-c and Supplementary  Fig. 10 ). Lgr5 was also expressed at the polyp base, where a proportion of Dclk1-positive tumor cells was positive for Lgr5 ( Fig. 3d-g ). Combined with the finding that Dclk1-positive cell lineages seemed to be generated from Dclk1-positive cells at the polyp base ( Fig. 2h-l) , we hypothesized that the Dclk1 + Lgr5 + double-positive cells located at the polyp base were candidate TSCs in Apc Min/+ mice. Notably, few Dclk1-positive cells exhibited apoptosis (Fig. 3h,i ). This suggests that Dclk1 might confer an anti-apoptotic property to TSCs, in accordance with a previous report 25 .
We then investigated the hierarchy between Dclk1 and Lgr5. Lgr5 CreERT2/+ ; Ctnnb1 lox(ex3)/+ mice, in which Cre recombination removes exon 3 of Ctnnb1 to stabilize β-catenin 26 , developed numerous intestinal polyps 40 d after tamoxifen injection ( Supplementary  Fig. 11a-d) , as expected 27 . We found that Dclk1-positive tumor cells colocalized with Lgr5-positive cells at the base of these polyps (Supplementary Fig. 12 ). In contrast, Dclk1 CreERT2/+ ; Ctnnb1 lox(ex3)/+ mice did not develop intestinal polyps, even 45 d after injection ( Supplementary Fig. 11e-g ). These data suggest that Dclk1-positive cells in the normal intestine did not transform into TSCs directly and that Dclk1 expression arose secondarily in Lgr5-positive TSCs.
To ensure that Dclk1 + Lgr5 + cells were true TSCs, we compared the Dclk1 − Lgr5 − , Dclk1 + Lgr5 − , Dclk1 − Lgr5 + and Dclk1 + Lgr5 + tumor cell populations by fluorescence-activated cell sorting (FACS) analyses. Flow cytometry showed that staining with antibody to Dclk1 gave results agreeing with those from measurement of Dclk1-green fluorescent protein (GFP), and the knockin cassette was restricted to Dclk1-positive cells in the polyps of Dclk1 CreERT2−IRES−EGFP/+ ; Apc Min/+ mice ( Supplementary Fig. 13a,b) . We sorted tumor cells on the basis of the expression of Dclk1 and Lgr5-GFP in polyps from Lgr5 EGFP−IRES−CreERT2/+ ; Ctnnb1 lox(ex3)/+ mice, and the proportion of Dclk1 + Lgr5 + tumor cells in the total Dclk1-positive cell population was found to be 5.3% (Fig. 4a) , in accordance with our immunohistochemical data. Flow cytometry showed that, of the four cell populations, expression of the representative TSC markers CD44 and CD133 was highest in Dclk1 + Lgr5 + cells (Fig. 4b,c) . Dclk1 + Lgr5 + tumor cells also showed the highest expression of Bcl2, a representative anti-apoptotic protein (Fig. 4d) . Subsequently, we collected Lgr5-positive tumor cells (Supplementary Fig. 13c ), which were doubly stained with antibodies against Dclk1 and proliferative or apoptotic markers. We occasionally observed Ki67-positive proliferative cells among the Dclk1 + Lgr5 + cells, whereas we rarely detected TUNEL-positive apoptotic cells (Fig. 4e-h) . Expression of Cox-1, a Tuft cell marker, was higher in Dclk1 + Lgr5 + and Dclk1 + Lgr5 − tumor cells (Supplementary Fig. 13d) . Overall, these results suggest that Dclk1 + Lgr5 + cells have the potential of TSCs, with an anti-apoptotic character 28, 29 . npg l e t t e r s
Finally, we investigated whether targeting TSCs marked by Dclk1 could be an effective antitumor therapy. In Dclk1 CreERT2/+ ; Rosa26R; Apc Min/+ ; Rosa26 iDTR/+ mice, Cre activation induces the diphtheria toxin receptor in Dclk1-positive cells, and administration of diphtheria toxin results in the death of these cells 30, 31 (Fig. 5a) . After tamoxifen and diphtheria toxin treatment, LacZ-labeled cells were absent in the normal intestine, without substantial damage to organ architecture (Fig. 5b-e) . Even when diphtheria toxin was administered three times daily for 3 d until 24 h after tamoxifen injection, we found no significant damage to normal tissues ( Supplementary  Fig. 14) . In contrast, we observed severely injured or collapsed polyps over time after a single diphtheria toxin treatment (Fig. 5f-j) . To confirm that diphtheria toxin specifically induced the apoptosis of Dclk1-positive cells, we examined the apoptotic status of Dclk1-positive and Dclk1-negative tumor cells after diphtheria toxin treatment. We observed apoptotic Dclk1-positive tumor cells at 12 h after diphtheria toxin injection, but the apoptotic status of Dclk1-negative tumor cells was not affected (Fig. 5k and Supplementary Fig. 15a,b) . At later time points, Dclk1-positive tumor cells were absent, and the proportion of total apoptotic cells returned to the basal level (Supplementary Fig. 15 ). These data suggest that diphtheria toxin successfully eliminated only Dclk1-positive cells without affecting other tumor cells. Combined with the finding that the turnover rate of polyps was approximately 7 d, it seems that interruption of the tumor progeny supply by Dclk1-positive TSCs resulted in tumor regression during this period.
In this study, we have shown that Dclk1 does not mark NSCs but marks TSCs that are capable of continuously producing tumor progeny in the intestine of Apc Min/+ mice (Fig. 6) . Our lineage-tracing analyses showed that the intestinal polyps of Apc Min/+ mice have a rapid turnover rate organized by TSCs. We suggest that Dclk1 and Lgr5 double-positive cells at the tumor base have properties of TSCs in a hierarchical system in mouse intestinal adenoma, which agrees with a previous report that stem cell-like tumor cells exist at the base of human CRCs 32 . Other stem cell markers may substitute for Lgr5 as a partner of Dclk1 because Dclk1 and Lgr5 double-positive cells had higher expression of CD44 and CD133. Even so, it is particularly notable that the specific ablation of Dclk1-positive TSCs resulted in tumor regression without substantial damage to normal tissues (Fig. 6c) . Although we implemented a restrictive ablation method to specifically kill TSCs, it remains possible that diphtheria toxin treatment affects the immediate progeny and not only TSCs because of technical limitations. However, our analysis of the apoptosis of Dclk1-positive and other tumor cells suggests that diphtheria toxin specifically targeted Dclk1-positive cells and caused tumor regression. Thus, Dclk1 seems to be a unique marker for distinguishing TSCs from intestinal NSCs. The similar Dclk1 expression pattern in humans and mice (Supplementary Fig. 1 ) leads us to propose the possibility of targeting Dclk1-positive tumor cells for the treatment of human CRCs. This study thus provides new insights into the therapeutic potential of targeting cancer stem cells.
MeThODS
Methods and any associated references are available in the online version of the paper. npg
ONLINe MeThODS
Mice. Dclk1-CreERT2-IRES-EGFP mice were generated by high-fidelity PCR from genomic BAC clone RP23-132B14, 2.5 kb upstream of the ATG start codon of the mouse Dclk1 gene and 6.1 kb downstream of the end of exon 2. After sequencing, these Dclk1-flanking arms were cloned into pBluescriptII SK + plasmid containing the CreERT2-IRES-EGFP cassette, as depicted in Supplementary Figure 2 . The expression construct (25 µg) was linearized and transfected into C57BL/6 mouse embryonic stem (ES) cells by electroporation. Neomycin-resistant recombinant ES clones were selected in medium containing G418 for 7 d. A total of 231 recombinant ES clones were transferred into 96-well plates and cultured to 70% confluence. Plates were then duplicated, with one cryopreserved and one continued in culture to 100% confluence for DNA isolation. DNA from all clones was screened for correct targeting by long-range PCR with primers flanking the 5′ short arm. All positive clones and randomly selected negative clones were then confirmed by Southern blotting using the 5′ and 3′ probes indicated in Supplementary  Figure 2 . Six positive clones were thawed, expanded and injected into BALB/c blastocysts using standard procedures. Male chimeras born after transplantation of the blastocysts into ICR foster mothers were subsequently mated with C57BL/6 females, and germline transmission was confirmed by screening offspring for the presence of the expression cassette in the Dclk1 locus by PCR. In the single-dose injection protocol, diphtheria toxin was given 24 h after tamoxifen administration. In the multiple-dose injection protocol, diphtheria toxin was given three times daily with 8-h intervals for 3 d, and the final injection was applied 24 h after tamoxifen administration. It has been reported that the serum concentration of diphtheria toxin that we used in our experiments decreases to <15% of the maximum concentration 24 h after the injection 30 .
To support the notion that Dclk1-positive cells were specifically killed by diphtheria toxin and that their progeny were unaffected by diphtheria toxin, which might persist until later time points, we injected 15 ng of diphtheria toxin (15% of the dose we used in the ablation experiment) into Dclk1 CreERT2/+ ; Rosa26R; Apc Min/+ ; Rosa26 iDTR/+ mice. In this experiment, the number of blue cells in the normal intestine and blue polyps was not decreased after diphtheria toxin injection (Supplementary Fig. 16 ), indicating that Dclk1-positive cells were not killed by this low-dose diphtheria toxin protocol. This finding suggests that a single injection of 100 ng of diphtheria toxin did not have a substantial effect the day after diphtheria toxin injection in our ablation model.
Injury models.
Injury experiments were performed using >8-week-old mice.
For the irradiation-induced injury model, mice were exposed to 8 Gy of irradiation. For the dextran sodium sulfate (DSS)-induced colitis model, mice were exposed to 2.0% DSS (MP Biomedicals) given in drinking water for 7 d consecutively. In both models, a single tamoxifen injection (4 mg) was given just before the end of injury.
Histological analysis. For histological analysis, mouse organs were isolated and fixed overnight in 4% paraformaldehyde, embedded in paraffin and sectioned at a thickness of 3-5 µm. Fig. 1g and 3a-c) , 300 µl of BrdU (Roche) was injected into the mice 2 h before they were sacrificed. For the BrdU pulse-chase study (Supplementary Fig. 8 ), 300 µl of BrdU was injected into 14-week-old Apc Min/+ mice three times at 3-h intervals. Tissues or sorted tumor cells were stained using the 5′-Bromo-2′-deoxyuridine Labeling & Detection kit as recommended by the manufacturer (Roche). TUNEL staining was performed using the In Situ Cell Death Detection kit, TMR red (Roche).
b-galactosidase (LacZ) staining protocol. Organs were isolated and immediately incubated for 2 h in a 20-fold volume of ice-cold fixative solution (PBS containing 4% paraformaldehyde, 5 mM EGTA, 2 mM MgCl 2 , 0.2% glutaraldehyde and 0.02% NP-40) at 4 °C on a rolling platform. Small intestine and colon were first cleaned by flushing with PBS to remove feces. Fixative was removed, and tissues were washed twice in PBS for 20 min at room temperature (20 °C) on a rolling platform. β-galactosidase substrate (PBS containing 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 0.02% NP40, 0.1% sodium deoxycholate and 1 mg/ml X-galactosidase) was then added, and tissues were incubated in the dark overnight at room temperature. Substrate was removed, and tissues were washed twice in PBS for 20 min at room temperature. Tissues were then fixed overnight in a 20-fold volume of 4% paraformaldehyde in PBS at 4 °C in the dark on a rolling platform. Paraformaldehyde was removed, and the stained tissues were transferred to tissue cassettes. Paraffin blocks were prepared using standard methods, and tissue sections (5 µm) were prepared and counterstained with nuclear fast red (KPL). 
